Rheumatoid Arthritis DMARD Intervention and UtilizationStudy

Last updated: May 5, 2011
Sponsor: Amgen
Overall Status: Completed

Phase

N/A

Condition

Bone Diseases

Dermatomyositis (Connective Tissue Disease)

Rheumatoid Arthritis

Treatment

N/A

Clinical Study ID

NCT00116727
20021635
016.0035
  • Ages > 18
  • All Genders

Study Summary

To systematically collect and document use patterns, effectiveness and safety of DMARD treatments currently used in the management of rheumatoid arthritis. The primary purpose of this study is to estimate the incidence of serious adverse experiences and adverse experiences of interest in patients with rheumatoid arthritis (RA) treated with ENBREL®.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Fulfillment of the 1987 American Rheumatism Association criteria for RA

  • Currently requiring the addition of ENBREL® therapy (to be taken alone or in additionto their current DMARD therapy)

Exclusion

Exclusion Criteria:

  • Currently or previously enrolled in RADIUS 1

  • Currently enrolled in a clinical trial where treatments or patient visits are imposedby a protocol

  • Active infections

  • Known allergy to ENBREL® or any of its components

  • Current treatment with ENBREL®

  • Patients who have previously been demonstrated to be intolerant of or refractory toENBREL® therapy

  • Nursing or pregnant women

Study Design

Total Participants: 5103
Study Start date:
October 01, 2002
Estimated Completion Date:
October 31, 2008